Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Page 13 of 23
May 1, 2026This strategic expansion underlines Novartis’s commitment to solidifying its manufacturing footprint in the US and leveraging the North Carolina biotech cluster. The API plant equips the company with end-to-end production capacity critical for future pharmaceutical innovation and supply chain resilience.
Daniel Cho
May 1, 2026Amgen's investigational drug MariTide represents a significant innovation in managing obesity by potentially enabling monthly or less frequent dosing schedules, promising enhanced patient adherence and convenience. This approach could position MariTide as a competitive solution in the obesity drug market, addressing treatment adherence challenges and meeting a substantial unmet medical need.
Dr. Priya Nandakumar
May 1, 2026The healthcare sector in April 2026 experienced a whirlwind of personnel changes that reflect broader trends in the industry’s adaptation to evolving market demands and operational challenges. This post unpacks the key developments across leading companies and organizations.
Emily Carter
Apr 29, 2026The pharmaceutical giant Pfizer has secured a legal settlement that delays generic competition for one of its top-selling drugs until 2031. This move has important implications for the pharmaceutical industry, generic manufacturers, and patients worldwide. The settlement highlights ongoing tensions between innovator companies and generic drugmakers, regulatory landscapes influencing market dynamics, and the strategic measures companies take to protect valuable assets.
Michael Torres
Apr 29, 2026This strategic deal marks a significant expansion in AbbVie's oncology portfolio by focusing on the challenging KRAS mutation. It reflects broader biotech industry trends toward targeted therapies for difficult-to-treat cancers and includes detailed financial structures and risk assessments.
Dr. Alex Morgan
Apr 28, 2026With the appointment of Ramin H. Garijo as the new CEO of Sanofi, the pharmaceutical giant faces the challenge of easing its dependency on Dupixent, a core revenue driver. This leadership change opens a window for strategic diversification and innovation within the company.
Jonathan Blake
Apr 22, 2026After partnering in early 2021 to develop RIPK1 blockers, Eli Lilly has disengaged from its alliance with Rigel Pharmaceuticals. This move follows Lilly's earlier withdrawal from one CNS-targeted program, highlighting the complexities and hurdles faced in advancing RIPK1 inhibitors. This post explores the implications of this development for the RIPK1 field and the broader pharmaceutical landscape.
Michael Torres
Apr 21, 2026The acquisition of Kelonia Therapeutics marks a significant milestone in Eli Lilly’s ongoing commitment to in vivo genetic medicine. This deal complements their recent strategic purchases and underscores a focused expansion into cell therapy fields such as CAR-T, aiming to bring novel treatments for multiple myeloma to clinical fruition.
Jonathan Blake
Apr 18, 2026Trilliant Health's recent report reveals a dramatic 62% surge in behavioral health demand over the past several years. Despite this growth, systemic issues such as clinician shortages and accessibility challenges continue to impede care delivery, underscoring the complex landscape facing the behavioral health industry today.
Michael Torres
Apr 15, 2026Amid an ongoing reevaluation of its business alliances, Takeda is narrowing its focus by cutting ties with Veritas In Silico, a biotech firm known for its novel mRNA-targeting small molecule drug development. This decision follows Takeda’s earlier separation from Denali Therapeutics, reflecting a continued pattern of partnership pruning intended to concentrate efforts and resources on prioritized projects and technologies.
Sophia Reynolds
Apr 15, 2026In recent transactions, leading biopharma companies such as Gilead, AstraZeneca, and Vertex have pursued acquisitions that emphasize the value of skilled staff and research teams. This trend marks a strategic focus on human capital as a key driver of innovation and competitive advantage in the sector.
Michael Torres
Apr 14, 2026Pharmaceutical companies are entering the first quarter earnings reports season with anticipation focused on innovative drugs and strategic deals. Novo Nordisk will lead with revealing revenue numbers from its oral GLP-1 medication, setting the pace for discussions around approvals, pricing, and external economic pressures including new tariffs.
Emily CarterMachine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.